Kronos Bio (KRON) Stock Forecast, Price Target & Predictions
KRON Stock Forecast
Kronos Bio stock forecast is as follows: an average price target of $7.63 (represents a 703.16% upside from KRON’s last price of $0.95) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
KRON Price Target
The average price target for Kronos Bio (KRON) is $7.63 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $2.25. This represents a potential 703.16% upside from KRON's last price of $0.95.
KRON Analyst Ratings
According to 4 Wall Street analysts, Kronos Bio's rating consensus is 'Buy'. The analyst rating breakdown for KRON stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Kronos Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 03, 2024 | Robert Burns | H.C. Wainwright | $2.25 | $1.03 | 118.45% | 136.84% |
| May 23, 2022 | - | Piper Sandler | $13.00 | $3.81 | 241.21% | 1268.42% |
The latest Kronos Bio stock forecast, released on May 03, 2024 by Robert Burns from H.C. Wainwright, set a price target of $2.25, which represents a 118.45% increase from the stock price at the time of the forecast ($1.03), and a 136.84% increase from KRON last price ($0.95).
Kronos Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $2.25 |
| Last Closing Price | $0.95 | $0.95 | $0.95 |
| Upside/Downside | -100.00% | -100.00% | 136.84% |
In the current month, the average price target of Kronos Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Kronos Bio's last price of $0.95. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Dec 19, 2023 | Raymond James | Buy | Buy | Hold |
| May 24, 2022 | Goldman Sachs | Buy | Buy | Hold |
| May 23, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Feb 28, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Kronos Bio's last stock rating was published by H.C. Wainwright on May 03, 2024. The company gave KRON a "Buy" rating, the same as its previous rate.
Kronos Bio Financial Forecast
Kronos Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $2.29M | $917.00K | $1.86M | $1.22M |
| Avg Forecast | $333.33K | $333.33K | $1.18M | $1.18M | $2.10M | $2.10M | $1.52M | $1.00M | $1.52M | $1.40M | $1.67M | $5.63M |
| High Forecast | $396.82K | $396.82K | $1.40M | $1.40M | $2.50M | $3.00M | $1.82M | $1.19M | $2.03M | $1.67M | $1.98M | $6.70M |
| Low Forecast | $158.73K | $158.73K | $559.88K | $559.88K | $999.05K | $1.20M | $726.19K | $476.19K | $1.02M | $666.67K | $793.65K | $2.68M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | 1.50% | 0.66% | 1.12% | 0.22% |
Kronos Bio's average Quarter revenue forecast for Mar 24 based on 1 analysts is $1.00M, with a low forecast of $476.19K, and a high forecast of $1.19M. KRON's average Quarter revenue forecast represents a -56.26% decrease compared to the company's last Quarter revenue of $2.29M (Dec 23).
Kronos Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $-26.87M | $-33.83M | $-32.17M | $-28.49M |
| Avg Forecast | $200.00K | $200.00K | $705.45K | $705.45K | $1.26M | $1.26M | $915.00K | $600.00K | $915.00K | $840.00K | $1.00M | $3.38M |
| High Forecast | $238.09K | $238.09K | $839.82K | $839.82K | $1.50M | $1.80M | $1.09M | $714.28K | $1.22M | $1000.00K | $1.19M | $4.02M |
| Low Forecast | $95.24K | $95.24K | $335.93K | $335.93K | $599.43K | $720.00K | $435.71K | $285.71K | $610.00K | $400.00K | $476.19K | $1.61M |
| Surprise % | - | - | - | - | - | - | - | - | -29.36% | -40.27% | -32.17% | -8.44% |
undefined analysts predict KRON's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Kronos Bio's previous annual EBITDA (undefined) of $NaN.
Kronos Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $-25.32M | $-31.37M | $-29.74M | $-23.41M |
| Avg Forecast | $-22.04M | $-21.24M | $-20.28M | $-17.88M | $-18.18M | $-16.68M | $-20.13M | $-25.39M | $-31.55M | $-30.80M | $-27.65M | $-26.74M |
| High Forecast | $-7.03M | $-6.78M | $-6.47M | $-5.70M | $-5.80M | $-12.83M | $-6.42M | $-8.10M | $-29.70M | $-9.83M | $-8.82M | $-8.53M |
| Low Forecast | $-27.49M | $-26.49M | $-25.31M | $-22.31M | $-22.68M | $-19.24M | $-25.12M | $-31.68M | $-32.79M | $-38.43M | $-34.49M | $-33.37M |
| Surprise % | - | - | - | - | - | - | - | - | 0.80% | 1.02% | 1.08% | 0.88% |
Kronos Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KRON's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Kronos Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $10.93M | $9.40M | $11.36M | $10.06M |
| Avg Forecast | $669.12K | $669.12K | $2.36M | $2.36M | $4.21M | $4.22M | $3.06M | $2.01M | $3.06M | $2.81M | $3.35M | $11.29M |
| High Forecast | $796.57K | $796.57K | $2.81M | $2.81M | $5.01M | $6.02M | $3.64M | $2.39M | $4.08M | $3.35M | $3.98M | $13.44M |
| Low Forecast | $318.63K | $318.63K | $1.12M | $1.12M | $2.01M | $2.41M | $1.46M | $955.88K | $2.04M | $1.34M | $1.59M | $5.38M |
| Surprise % | - | - | - | - | - | - | - | - | 3.57% | 3.34% | 3.40% | 0.89% |
Kronos Bio's average Quarter SG&A projection for Mar 24 is $2.01M, based on 1 Wall Street analysts, with a range of $955.88K to $2.39M. The forecast indicates a -81.63% fall compared to KRON last annual SG&A of $10.93M (Dec 23).
Kronos Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | $-0.43 | $-0.00 | $-0.52 | $-0.41 |
| Avg Forecast | $-0.37 | $-0.35 | $-0.34 | $-0.30 | $-0.30 | $-0.28 | $-0.34 | $-0.42 | $-0.53 | $-0.51 | $-0.46 | $-0.45 |
| High Forecast | $-0.12 | $-0.11 | $-0.11 | $-0.09 | $-0.10 | $-0.21 | $-0.11 | $-0.13 | $-0.49 | $-0.16 | $-0.15 | $-0.14 |
| Low Forecast | $-0.46 | $-0.44 | $-0.42 | $-0.37 | $-0.38 | $-0.32 | $-0.42 | $-0.53 | $-0.55 | $-0.64 | $-0.57 | $-0.56 |
| Surprise % | - | - | - | - | - | - | - | - | 0.82% | 0.00% | 1.13% | 0.92% |
According to undefined Wall Street analysts, Kronos Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KRON previous annual EPS of $NaN (undefined).
Kronos Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KRON | Kronos Bio | $0.95 | $7.63 | 703.16% | Buy |
| LYEL | Lyell Immunopharma | $1.23 | $9.50 | 672.36% | Hold |
| SPRO | Spero Therapeutics | $1.37 | $10.00 | 629.93% | Buy |
| CTMX | CytomX Therapeutics | $1.23 | $5.77 | 369.11% | Buy |
| GOSS | Gossamer Bio | $0.92 | $3.75 | 307.61% | Buy |
| ADXN | Addex Therapeutics | $9.64 | $30.00 | 211.20% | Buy |
| ACHL | Achilles Therapeutics | $0.72 | $2.00 | 177.78% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| ERAS | Erasca | $2.97 | $7.00 | 135.69% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| NXTC | NextCure | $1.40 | $3.00 | 114.29% | Buy |
| LRMR | Larimar Therapeutics | $7.20 | $14.50 | 101.39% | Buy |
| LYRA | Lyra Therapeutics | $0.28 | $0.50 | 78.57% | Hold |
| CCCC | C4 Therapeutics | $6.44 | $11.33 | 75.93% | Hold |
| MRUS | Merus | $50.14 | $77.86 | 55.29% | Buy |
| CRNX | Crinetics Pharmaceuticals | $53.80 | $70.14 | 30.37% | Buy |
KRON Forecast FAQ
Is Kronos Bio a good buy?
Yes, according to 4 Wall Street analysts, Kronos Bio (KRON) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of KRON's total ratings.
What is KRON's price target?
Kronos Bio (KRON) average price target is $7.63 with a range of $2.25 to $13, implying a 703.16% from its last price of $0.95. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Kronos Bio stock go up soon?
According to Wall Street analysts' prediction for KRON stock, the company can go up by 703.16% (from the last price of $0.95 to the average price target of $7.63), up by 1268.42% based on the highest stock price target, and up by 136.84% based on the lowest stock price target.
Can Kronos Bio stock reach $1?
KRON's average twelve months analyst stock price target of $7.63 supports the claim that Kronos Bio can reach $1 in the near future.
What are Kronos Bio's analysts' financial forecasts?
Kronos Bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $6.72M (high $8.5M, low $3.4M), average EBITDA is $4.03M (high $5.1M, low $2.04M), average net income is $-80.383M (high $-33.154M, low $-98.723M), average SG&A $13.5M (high $17.07M, low $6.83M), and average EPS is $-1.337 (high $-0.552, low $-1.643). KRON's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.02M (high $3.59M, low $1.44M), average EBITDA is $1.81M (high $2.16M, low $862.33K), average net income is $-81.435M (high $-25.982M, low $-102M), average SG&A $6.06M (high $7.21M, low $2.88M), and average EPS is $-1.355 (high $-0.432, low $-1.691).
Did the KRON's actual financial results beat the analysts' financial forecasts?
Based on Kronos Bio's last annual report (Dec 2023), the company's revenue was $6.29M, which missed the average analysts forecast of $10.22M by -38.45%. Apple's EBITDA was $-122M, missing the average prediction of $6.13M by -2087.44%. The company's net income was $-113M, missing the average estimation of $-117M by -3.49%. Apple's SG&A was $41.74M, beating the average forecast of $20.51M by 103.52%. Lastly, the company's EPS was $-1.95, beating the average prediction of $-1.943 by 0.39%. In terms of the last quarterly report (Dec 2023), Kronos Bio's revenue was $2.29M, beating the average analysts' forecast of $1.52M by 49.90%. The company's EBITDA was $-26.866M, missing the average prediction of $915K by -3036.17%. Kronos Bio's net income was $-25.32M, missing the average estimation of $-31.552M by -19.75%. The company's SG&A was $10.93M, beating the average forecast of $3.06M by 256.92%. Lastly, the company's EPS was $-0.43, missing the average prediction of $-0.525 by -18.10%